| pubmed-article:9746768 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0037047 | lld:lifeskim |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0018133 | lld:lifeskim |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0085149 | lld:lifeskim |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0282461 | lld:lifeskim |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0729218 | lld:lifeskim |
| pubmed-article:9746768 | lifeskim:mentions | umls-concept:C0678125 | lld:lifeskim |
| pubmed-article:9746768 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:9746768 | pubmed:dateCreated | 1998-10-19 | lld:pubmed |
| pubmed-article:9746768 | pubmed:abstractText | We report the results of a phase III open-label, randomized, multicenter trial comparing tacrolimus/methotrexate to cyclosporine/methotrexate for graft-versus-host disease (GVHD) prophylaxis after HLA-identical sibling marrow transplantation in patients with hematologic malignancy. The primary objective of this study was to compare the incidence of moderate to severe (grade II-IV) acute GVHD. Secondary objectives were to compare the relapse rate, disease-free survival, overall survival, and the incidence of chronic GVHD. Patients were stratified according to age (<40 v >/=40) and for male recipients of a marrow graft from an alloimmunized female. There was a significantly greater proportion of patients with advanced disease randomized to tacrolimus arm (P = . 02). The incidence of grade II-IV acute GVHD was significantly lower in patients who received tacrolimus than patients in the cyclosporine group (31.9% and 44.4%, respectively; P = .01). The incidence of grade III-IV acute GVHD was similar, 17.1% in cyclosporine group and 13.3% in the tacrolimus group. There was no difference in the incidence of chronic GVHD between the tacrolimus and the cyclosporine group (55.9% and 49.4%, respectively; P = .8). However, there was a significantly higher proportion of patients in the cyclosporine group who had clinical extensive chronic GVHD (P = . 03). The relapse rates of the two groups were similar. The patients in the cyclosporine arm had a significantly better 2-year disease-free survival and overall survival than patients in the tacrolimus arm, 50.4% versus 40.5% (P = .01) and 57.2% versus 46.9% (P = .02), respectively. The significant difference in the overall and disease-free survival was largely the result of the patients with advanced disease, 24.8% with tacrolimus versus 41.7% with cyclosporine (P = .006) and 20.4% with tacrolimus versus 28% with cyclosporine (P = .007), respectively. There was a higher frequency of deaths from regimen-related toxicity in patients with advanced disease who received tacrolimus. There was no difference in the disease-free and overall survival in patients with nonadvanced disease. These results show the superiority of tacrolimus/methotrexate over cyclosporine/methotrexate in the prevention of grade II-IV acute GVHD with no difference in disease-free or overall survival in patients with nonadvanced disease. The survival disadvantage in advanced disease patients receiving tacrolimus warrants further investigation. | lld:pubmed |
| pubmed-article:9746768 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9746768 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9746768 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9746768 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9746768 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9746768 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9746768 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9746768 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9746768 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9746768 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:StorbRR | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:WeisdorfDD | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:BuellD NDN | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:Ratanatharath... | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:NashR ARA | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:FayJ WJW | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:PrzepiorkaDD | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:KleinJ LJL | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:HerzigR HRH | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:WingardJ RJR | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:WolffS NSN | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:MaherR MRM | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:LitzowM RMR | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:PetersenF BFB | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:AntinJ HJH | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:DevineS MSM | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:KaranesCC | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:NademaneeAA | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:AvalosBB | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:ChristiansenN... | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:FitzsimmonsW... | lld:pubmed |
| pubmed-article:9746768 | pubmed:author | pubmed-author:LongoW LWL | lld:pubmed |
| pubmed-article:9746768 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9746768 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9746768 | pubmed:volume | 92 | lld:pubmed |
| pubmed-article:9746768 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9746768 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9746768 | pubmed:pagination | 2303-14 | lld:pubmed |
| pubmed-article:9746768 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:meshHeading | pubmed-meshheading:9746768-... | lld:pubmed |
| pubmed-article:9746768 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9746768 | pubmed:articleTitle | Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. | lld:pubmed |
| pubmed-article:9746768 | pubmed:affiliation | University of Michigan, Ann Arbor; Fred Hutchinson Cancer Research Center, Seattle, WA, USA. vratanat@umich.edu | lld:pubmed |
| pubmed-article:9746768 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9746768 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9746768 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:9746768 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:9746768 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9746768 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9746768 | lld:pubmed |
